GSK’s Liquid Menveo Vaccine Gains EU Approval

GlaxoSmithKline (GB:GSK) has released an update.

GlaxoSmithKline (GSK) has received approval from the European Commission for its new fully liquid Menveo vaccine, which simplifies the vaccination process against invasive meningococcal disease by eliminating the need for reconstitution. This approval expands the options for healthcare providers to immunize children, adolescents, and adults, supporting GSK’s ongoing commitment to combat serious bacterial infections. With this innovation, GSK aims to enhance vaccine uptake and provide a robust solution to protect at-risk populations across Europe.

For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.